Chemotherapy use in lung cancer patients during last three months of life: Current practice in a large Israeli health care organization.

e17675 Background: Lung cancer is the second leading cause of cancer-related death in Israel. Aggressive cancer treatment given at late stages of disease raises questions on quality of care, ethical aspects and cost. Objective: To explore the use of anti-cancer chemotherapeutic drugs (CT) in lung cancer patients (pts) that deceased during 2013, within three months of end of life (EOL). Methods: Clalit Health Services (CHS), Israelu0027s largest health-care organization with over 4 million members, serves 52% of the total population. CHSs administrative database was used to extract available clinical and demographic information regarding all of CHSu0027s Lung cancer pts that died during 2013. Data obtained included: cancer diagnoses, demographics, Charlsonu0027s comorbidity index and pharmacotherapy provided within 3 months of EOL. Results: 556 CHS pts died from lung cancer in 2013, 184 female (33%). 338 pts received CT within 3 months of EOL (table). Pts that received CT were significantly younger than pts that didnu0027...